Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Eli Lilly Sues Over Knock-Off Weight-Loss Drugs

Eli Lilly Sues Over Knock-Off Weight-Loss Drugs

Eli Lilly has filed three new separate lawsuits accusing vendors and a medical spa of selling knock-off versions of their drug, Zepbound.

International Business Times

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

UK regulator approves second Alzheimer's drug in months but government won't pay for it

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers

The Independent UK

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

The Independent UK

3 Healthcare Stocks That Can Thrive in Any Economy

The healthcare market shows promise due to heightened demand for quality care, technological advancements, preventive measures, and increased public investment, ensuring resilience in any economic condition. Therefore, investors could now consider top healthcare stocks, such as Eli Lilly (LLY), Merck & Co. (MRK), and Abbott Laboratories (ABT). Keep reading.

Nvidia's 84% Expected Profit Growth Looms Large In S&P 500

Nvidia is expected to boost the S&P 500 Q3 earnings growth rate. Meta Platforms and Alphabet may lift Communications Services earnings.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

Investors Business Daily

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

The Conversation

8 Stocks Poised To Report Nvidia-Beating Profit Growth Any Day Now

8 Stocks Poised To Report Nvidia-Beating Profit Growth Any Day Now

S&P 500 earnings season is kicking off. And some companies are expected to put up some huge numbers — even bigger than Nvidia

Investors Business Daily

Dow Jones Futures: Stock Market Rebounds As Nvidia, Robinhood Lead 11 Buys; AI Giant's Sales Strong

Dow Jones Futures: Stock Market Rebounds As Nvidia, Robinhood Lead 11 Buys; AI Giant's Sales Strong

The Nasdaq led Tuesday's market rebound. Nvidia powered past another buy point, with many other stocks actionable. AI giant Taiwan Semi reported strong sales.

Investors Business Daily

Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients

Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously, it was only available on the NHS for patients with diabetes.

The Conversation

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

3 Healthcare Stocks to Watch as the Aging Population Drives Demand

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding healthcare giants like Eli Lilly and Company (LLY), UnitedHealth Group (UNH), and Merck & Co. (MRK) to their watchlist. Read…

Investors Business Daily

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

Get all your
news in one place.

100’s of premium titles.
One news app.

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Investors Business Daily

Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points

Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.

International Business Times

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

Three stocks to note before the Fed rate cut decision

Here are the stocks making the biggest market moves.

Eli Lilly's Eczema Drug Gets FDA Approval, Injectable Treatment Available Within Weeks

The new injectable drug, Lebrikizumab, branded as Ebglyss, is approved for treating atopic dermatitis in adults and children aged 12 and older who weigh at least 88 pounds.

1 2 3 4 5

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

236,957 stories

100,198 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play